Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have jointly patented tricyclic compounds acting as mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors. As such, they are reported to be useful for the treatment of cancer and autoimmune diseases.
JS Innomed Holdings Ltd. and JS Innopharm Ltd. have developed new tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, LEOPARD syndrome and Noonan syndrome.
Indazole compounds acting as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors have been described in a recent Nippon Shinyaku Co. Ltd. patent as potentially useful for the treatment of irritable bowel syndrome, psoriasis, arthritis, bacterial infection, systemic lupus erythematosus, pancreatitis, asthma and chronic obstructive pulmonary disease, among others.
Haisco Pharmaceutical Group Co. Ltd. has described propionic acid derivatives acting as integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory disorders.
Suzhou Ark Biopharmaceutical Co. Ltd. researchers have prepared and tested heteroaromatic bicyclic compounds reported to be useful for the treatment of respiratory syncytial virus (RSV) infection.
Research at Korea Research Institute of Chemical Technology (KRICT) has led to the identification of pyrazolopyrimidine-containing compounds acting as dual specificity protein kinase TTK (MPS1; MPS1L1) inhibitors and reported to be useful for the treatment of cancer.
858 Therapeutics Inc. has patented a series of 6,6-fused heterocyclic compounds acting as N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of acute myeloid leukemia.
Atai Life Sciences AG has described 5-HT2A receptor agonists reported to be useful for the treatment of substance abuse and dependence, treatment resistant depression, major depression, anxiety, eating, obsessive-compulsive and stress disorder.
Beigene Co. Ltd. has divulged antibody-drug conjugates (ADC) comprising HER3 (erbB3) targeting antibody linked to an effector molecule through a linker reported to be useful for the treatment of cancer, metabolic diseases, neurodegeneration and inflammation.
RSS
